Across TCGA pan-cancer cohorts, KIR2DS4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KIR2DS4 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher KIR2DS4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KIR2DS4 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
UCEC and SKCM are the cancer types where KIR2DS4 Mutation most reproducibly stratifies survival.